Budesonida CAS:51333-22-3

Budesonide is a glucocorticoid steroid for the treatment of asthma, COPD and non-infectious rhinitis (including hay fever and other allergies), and for treatment and prevention of nasal polyposis. In addition, it is used for inflammatory bowel disease. It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system.

Budesonide is nebulized for maintenance and prophylactic treatment of asthma. also for treatment and prevention of nasal polyposis. maintenance of remission (for up to 3 months) of Crohn's disease (mild-to-moderate) involving the ileum and/or ascending colon. Budesonide assists in the induction of remission in patients with active ulcerative colitis.

Budesonide, sold under the brand name Pulmicort among others, is a medication of the corticosteroid type.It is available as an inhaler, nebulization solution, pill, nasal spray, and rectal forms.The inhaled form is used in the long-term management of asthma and chronic obstructive pulmonary disease (COPD).The nasal spray is used for allergic rhinitis and nasal polyps.The pills in a delayed release form and rectal forms may be used for inflammatory bowel disease including Crohn's disease, ulcerative colitis, and microscopic colitis.

Common side effects with the inhaled form include respiratory infections, cough, and headaches.Common side effects with the pills include feeling tired, vomiting, and joint pains.Serious side effects include an increased risk of infection, loss of bone strength, and cataracts.Long-term use of the pill form may cause adrenal insufficiency. Stopping the pills suddenly following long-term use may therefore be dangerous.The inhaled form is generally safe in pregnancy.Budesonide chiefly acts as a glucocorticoid.

Budesonide was initially patented in 1973.Commercial use as an asthma medication began in 1981.It is on the World Health Organization's List of Essential Medicines.Some forms are available as a generic medication.In 2019, generic budesonide was listed as involved in Teva's price fixing scheme in the United States.In 2019, it was the 201st most commonly prescribed medication in the United States, with more than 2 million prescriptions.